Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14417 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Chris Armstrong und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Adult Stem Cell Transplant Centre, St. James' Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Lymphocyte Transfusion, Antilymphocyte Serum. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Fludarabine, busulfan, and anti‐T‐lymphocyte globulin (FLUBU3+ATLG) reduced‐intensity conditioning is an established preparative regimen for allogeneic haematopoietic stem cell transplantation in older patients with myeloid malignancy. We examined its modern‐day performance in 175 sequentially treated patients on our national programme. Overall survival was 72.4% at 2 years (95% CI 64.6%–78.6%) with a cumulative incidence of non‐relapse mortality of 11%. The cumulative 2‐year relapse incidence was 27% (95% CI 22.8%–37.6%) and was partially ameliorated by chronic graft‐versus‐host disease (HR 0.35, 95% CI 0.12–0.98, p = 0.02 ). Mixed donor chimerism was observed in 51.5% beyond day 90, but relapse was significantly reduced in these patients by adopting a pre‐emptive donor lymphocyte infusion (DLI) strategy (HR 0.22, 95% CI 0.07–0.69, p = 0.005 ). The use of DLI as part of post‐relapse salvage was also effective, with an improved median survival duration of 6 months in recipients (HR 0.43, 95% CI 0.18–0.98, p = 0.01 ). Outcomes in patients > 65 years and a limited cohort > 70 years are encouraging and compare favourably to published survival results using alternate reduced‐intensity regimens. FLUBU3+ATLG, supported by modern supportive care and a pre‐emptive DLI strategy, is well tolerated by older patients across a spectrum of myeloid disease with modest toxicity and favourable long‐term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Adult Stem Cell Transplant Centre, St. James' Hospital, Dublin, Ireland.
- Trinity College Dublin, The University of Dublin, Dublin, Ireland.
ORCID-Profile: Chris Armstrong
Zitieren
APA
Armstrong, C., Conneally, E., Flynn, C., Browne, P., Chonghaile, M. N., Galligan, C. A., Foy-Stones, H., Gardiner, N., Lee, G., & Orfali, N. (2025). Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy. European Journal of Haematology. https://doi.org/10.1111/ejh.14417
Vancouver
Armstrong C, Conneally E, Flynn C, Browne P, Chonghaile MN, Galligan CA, et al. Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy. European Journal of Haematology. 2025. doi:10.1111/ejh.14417
BibTeX
@article{Armstrong2025,
author = {Armstrong, Chris and Conneally, Eibhlin and Flynn, Catherine and Browne, Paul and Chonghaile, Mairead Ni and Galligan, Carmel Ann and Foy-Stones, Hayley and Gardiner, Nicola and Lee, Greg and Orfali, Nina},
title = {Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14417}
}
EUVIMED